Fig. 1: ATP6V1B2 has diagnostic value in the serum of patients with MASLD.
From: ATP6V1B2 alleviates hepatic steatosis by promoting lysosomal acidification in hepatocytes
A The relative levels of ATP6V1B2 were assessed in healthy individuals (n = 14) and patients with MASLD (n = 14) using data from the GSE126848 database. B The relative levels of ATP6V1B2 were evaluated across various MASH patients (n = 116) at different stages of the MASLD activity score (NAS) in the GSE162694 database. C The relative levels of ATP6V1B2 were assessed at various stages of liver fibrosis in patients with MASH (n = 143) from the GSE162694 database. D The relative levels of serum ATP6V1B2 were compared between healthy individuals (n = 66), patients diagnosed with MASLD (n = 58), and those with cirrhosis (n = 40). E ROC curves of serum ATP6V1B2 expression levels in healthy individuals (n = 66) and patients diagnosed with MASLD (n = 58). Serum F TC, G TG, H ALT, and I AST were analyzed for correlation with ATP6V1B2 in healthy individuals (n = 34) and MASLD patients (n = 34), respectively. J ROC curves of serum ATP6V1B2 change levels in healthy individuals (n = 66) and patients diagnosed with cirrhosis (n = 40). K Serum ALT, ATP6V1B2 correlation analysis in healthy individuals (n = 33) and patients diagnosed with cirrhosis (n = 37). L Serum AST, ATP6V1B2 correlation analysis in healthy individuals (n = 35) and patients diagnosed with cirrhosis (n = 39). *P < 0.05; **P < 0.01; ***P < 0.001.
